Dr. Adedayo A. Onitilo

About Adedayo A. Onitilo

Education:

• Earned an MD from Ogun State University, Sagamu, Nigeria in 1995.
• Completed internships in various specialties at General Hospital St. George's, Grenada (1997) and Ogun State University Teaching Hospital, Nigeria (1996).
• Achieved a PhD in Clinical Science from the University of Queensland, Australia in 2014.
• Obtained an MSCR from the Medical University of South Carolina in 2004.

Experience:

• Has been an Oncologist/Hematologist in Wisconsin since 2004, affiliated with institutions like Marshfield Medical Center and Ascension Saint Clare's Hospital.
• Serves as the Director of the Breast Program and Oncology Service Line Leader at Marshfield Clinic Inc., Eastern Division.
• Holds the position of Clinical Professor of Medicine at the University of Wisconsin Medical School since 2013.
• Actively involved in mentorship and research, including as Principal Investigator for the Wisconsin NCI Community Oncology Research Program.

Area of expertise

Affiliated Hospitals

Marshfield Medical Center-Marshfield

Marshfield Medical Center-EC Cancer Center

Clinical Trials Adedayo A. Onitilo is currently running

Mobile Health

for Breast Cancer

This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor. To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take them as prescribed, following a complex treatment schedule. Forgetfulness was the most common reason reported for medication non adherence. Using the WiseBag along with CONCURxP or enhanced usual care may improve medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor.

Recruiting

1 award

N/A

10 criteria

Combination Therapy

for Multiple Myeloma

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.

Recruiting

2 awards

Phase 3

32 criteria

More about Adedayo A. Onitilo

Clinical Trial Related

2 years of experience running clinical trials · Led 27 trials as a Principal Investigator · 11 Active Clinical Trials

Other Doctors you might be interested in

Frequently asked questions